Tatyana Worthy

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

Kevin C. Conlon, Enrico Lugli, Hugh C. Welles et al. · Journal of Clinical Oncology · 2014 · 686 citations · Full text

⁹⁰ Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma

John E. Janik, John C. Morris, Deirdre O’Mahony et al. · Proceedings of the National Academy of Sciences · 2015 · 49 citations · Full text

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Katherine E. Lindblad, Julie Thompson, Gege Gui et al. · Blood · 2018 · 29 citations

A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo‐immunized patients

Phuong Vo, Enkhtsetseg Purev, Kamille A. West et al. · British Journal of Haematology · 2020 · 28 citations · Full text

Immunology, Platelet Refractories, Immunotherapy +19

Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation

Emily McDuffee, Georg Aue, Lisa Cook et al. · Bone Marrow Transplantation · 2017 · 23 citations · Full text

Tumor Regression Concomitant, Radiation Oncology, Graft-versus-host Disease +15